High hopes for biotech companies / IPOs getting ready to go as startups woo VC investors
Biotechnology leaders are cautiously celebrating the end of a two- year financial slump this autumn as more than a dozen companies line up to go public and the latest class of young startups shows its stuff to potential venture capital partners at a conference in San Francisco today and Thursday.
Reducing Multi-Cycle Reviews Is FDA Priority
FDA Commissioner Mark McClellan today described key steps the agency is taking to shorten drug approval times, in his keynote speech at IIR�s Phases conference in Washington, D.C.
Reaping and Sewing From Corn
The National Renewable Energy Lab and chemical company DuPont have teamed to design a versatile bio-refinery that turns the entire corn plant into a source for materials and a petroleum alternate.
Rarely has a company reeling from corporate malfeasance been on the receiving end of so much good news. But such is the case with ImClone Systems, as investors struggle for clues on the long-term direction of this enigma.
IPO market abuzz with biotech offerings
The buzz is biotech — at least as far as initial public offerings are concerned in the fourth quarter.
IPO Market Abuzz with Biotech Offerings
“We can expect to see the first IPO take flight in mid-October and we are sticking with our prediction … of at least a dozen IPOs getting done before the end of the year.”
GE’s Genomic Future
On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and drug firms such as Roche and Abbott Laboratories.
Financial Snapshot For September 2003
A Temporary Pause
Medicine’s Big Bottleneck
If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.
Stem cell bill eyed as lure to biotech firms
A redraft may be in its future, but supporters of a proposed Bay State bill filed last winter that would formally welcome and set boundaries for stem cell research here say the measure will be an important part of the legislative agenda in the coming months.